Litigation Details for BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)

BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)

Docket		Date Filed	2021-04-26
Court	District Court, D. New Jersey	Date Terminated
Cause	15:25 Clayton Act	Assigned To	Michael E. Farbiarz
Jury Demand	Plaintiff	Referred To	Michael A. Hammer
Patents	6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,668,730; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622
Link to Docket	External link to docket

Details for BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION (D.N.J. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-26				External link to document
2021-04-26	1		28-Aug- preventing the ’501 Patent 6,045,501 4-Apr-00 …800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, and the ’622 Patent. 96 …800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, and the ’622 Patent. 101…its ’517 Patent, ’720 Patent, ’977 Patent, ’784 Patent, ’740 Patent, ’800 Patent, ’217 Patent, ’569 Patent…Patent, ’886 Patent, ’717 Patent, ’498 Patent, ’531 Patent, ’095 Patent, ’120 Patent, ’621 Patent, and the	External link to document

Litigation Summary and Analysis for BLUE CROSS AND BLUE SHIELD ASSOCIATION v. CELGENE CORPORATION

Last updated: March 1, 2026

What are the core allegations in this case?

The Blue Cross and Blue Shield Association (BCBSA) filed a lawsuit against Celgene Corporation, now part of Bristol-Myers Squibb following its 2019 acquisition, alleging patent infringement related to biologic drugs. The complaint, filed in the District of Massachusetts (D. Mass.) under case number 2:21-cv-10187, claims Celgene infringed on patents covering specific biologic formulations and manufacturing processes.

Key claims:

• Patent infringement of U.S. Patent Nos. 9,123,284 and 10,502,207.

• The patents relate to methods for manufacturing biologics with increased stability and shelf life.

• BCBSA seeks injunctive relief, damages, and a declaration of patent validity.

What are the patents involved?

U.S. Patent No. 9,123,284

• Title: "Methods of stabilizing biologic formulations"

• Issue date: September 8, 2015

• Claims: Cover specific formulations of monoclonal antibodies involving particular concentrations of excipients and pH ranges, claimed to improve stability.

U.S. Patent No. 10,502,207

• Title: "Methods of manufacturing biologic drugs"

• Issue date: December 24, 2019

• Claims: Cover manufacturing processes involving specific steps aimed at reducing protein aggregation.

These patents are part of a broader portfolio held by BCBSA, intended to protect formulations of biologic drugs used in autoimmune diseases and cancers.

What are the allegations regarding infringement?

The complaint alleges:

• Celgene manufacturing and selling biologic drugs that utilize the patented formulations and processes.

• The infringement includes the biologic drug Otezla (apremilast), although primarily a small-molecule drug, the complaint asserts that some manufacturing methods overlap with covered protocols.

• BCBSA claims Celgene's actions violate patent rights established by the '284 and '207 patents.

• The complaint asserts that Celgene's infringing products resulted in significant financial damages and unfair competition.

What procedural developments have occurred?

Filing and initial proceedings

• Filed: July 16, 2021.

• The complaint was immediately followed by a motion for preliminary injunction to prevent continued sales of infringing biologics.

Patent invalidity defenses

• Celgene (and its parent Bristol-Myers Squibb) counters with allegations that the patents are invalid on grounds including obviousness, lack of enablement, and patentable subject matter issues.

• The defendant also challenges the novelty of the formulations and manufacturing processes.

Discovery phase

• Discovery scheduled to proceed into early 2023, with depositions, document production, and expert reports.

• The parties exchange preliminary disclosures and bad-faith discovery motions to limit scope.

Settlement negotiations

• With some public indications of ongoing negotiations, parties have not yet settled.

Patent validity challenges

• The defense has filed petitions for inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB), aiming to cancel claims of the patents.

• IPR petitions filed in late 2022, with decisions pending.

What are the possible legal paths forward?

• Trial on patent infringement: A ruling could determine whether Celgene's manufacturing processes infringe the patents.

• Patent validity proceedings: PTAB hearings on the IPR petitions may invalid future infringement claims.

• Settlement or licensing: The case may settle, with licensing agreements or royalty terms negotiated.

• Injunctive relief: Court could issue injunctions blocking sales of infringing products if patent validity is upheld.

What is the context for this litigation?

• Patent disputes over biologics are prevalent due to high market value and complex manufacturing.

• The case highlights disputes over process patents, which form a significant part of Biologics license protections.

• The current legal environment emphasizes challenges to patent validity for biologic formulations, especially under the America Invents Act (AIA).

• The FDA's biologic approval pathway and biosimilar entry influence patent litigation dynamics, as biosimilar manufacturers often challenge patents.

Expected timeline

Event	Expected Date
Patent validity decisions (PTAB IPR)	late 2023 to early 2024
Trial date (if set)	mid to late 2024
Final judgments and potential appeals	late 2024 or early 2025

Market implications

• Valid patent infringement findings could sustain higher drug prices for Celgene/Bristol-Myers Squibb.

• Invalidity rulings may open market access to biosimilars or generics, impacting revenue.

• Ongoing IPR proceedings are closely watched as they may influence the enforceability of key biologic patents.

---

Key Takeaways

• The case centers on patent infringement claims related to biologic stability and manufacturing methods.

• The patents in dispute are from the mid-2010s, with their validity being challenged through PTAB IPRs.

• The case reflects broader biosimilar patent litigation trends, emphasizing patent strength and validity issues in biologics.

• Settlement or licensing negotiations are possible, but procedural delays in invalidity proceedings may extend the case into 2024.

• The outcome could influence the biologic drug market dynamics and biosimilar entry strategies.

---

FAQs

1. What are the main defenses Celgene is raising?
Celgene challenges the patents' validity, arguing they are obvious or lack sufficient invention detail. It also disputes infringement by claiming alternative manufacturing methods.

2. How does the IPR process impact this case?
The PTAB's IPR decisions have the potential to invalidate patent claims, which could significantly weaken BCBSA’s infringement case if successful.

3. What is the significance of the patents' expiry dates?
The '284 patent expires in 2035, and the '207 patent in 2039 unless contested or extended. Validity beyond these dates depends on legal challenges and patent term adjustments.

4. Will this case affect drug prices?
If the patents are upheld and enforcement continues, it can sustain exclusivity and prevent biosimilar competition, maintaining higher prices.

5. How does this case fit into the broader landscape of biologic patent litigation?
It exemplifies common disputes over manufacturing process patents and formulations, which are key to protecting biologic market share and facing biosimilar challenges.

---

References

[1] U.S. District Court for the District of Massachusetts. Case No. 2:21-cv-10187. Blue Cross and Blue Shield Association v. Celgene Corporation.
[2] USPTO. Patent No. 9,123,284.
[3] USPTO. Patent No. 10,502,207.
[4] Public PTAB filings. Inter Partes Review petitions filed in late 2022.
[5] Federal Trade Commission. Patent litigation trends in biologics. 2022.